TRAVERSE followed more than 5,000 men with low testosterone and existing heart disease or serious cardiovascular risk factors to determine whether testosterone therapy increased their risk of cardiac events. The TRAVERSE trial, the largest randomized study ever built to answer that question, finally gave doctors and patients firm ground to stand on. Its results carry weight for anyone weighing hormone therapy against cardiovascular risk. How the TRAVERSE study workedTRAVERSE was a multicenter, randomized, double-blind, placebo-controlled trial. Why the testosterone and heart findings matterA primary endpoint event occurred in 182 patients, or 7.0%, in the testosterone group.